Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) has received an average rating of “Buy” from the sixteen brokerages that are covering the firm. Seven equities research analysts have rated the stock with a hold rating and nine have issued a buy rating on the company. The average 12-month price target among analysts that have covered the stock in the last year is $61.93.

Several brokerages have commented on ALNY. Chardan Capital boosted their target price on shares of Alnylam Pharmaceuticals from $73.00 to $89.00 and gave the stock a “buy” rating in a research report on Wednesday. Jefferies Group decreased their price objective on shares of Alnylam Pharmaceuticals from $86.00 to $58.00 and set a “buy” rating on the stock in a research report on Thursday, October 6th. JPMorgan Chase & Co. boosted their price objective on shares of Alnylam Pharmaceuticals from $80.00 to $83.00 and gave the stock an “overweight” rating in a research report on Friday, August 5th. Stifel Nicolaus decreased their price objective on shares of Alnylam Pharmaceuticals from $68.00 to $36.00 and set a “hold” rating on the stock in a research report on Thursday, October 6th. Finally, Barclays PLC reiterated a “hold” rating and issued a $50.00 price objective on shares of Alnylam Pharmaceuticals in a research report on Thursday, November 3rd.

TRADEMARK VIOLATION WARNING: This news story was first published by Financial Market News and is owned by of Financial Market News. If you are viewing this news story on another publication, it was illegally stolen and reposted in violation of United States & international copyright laws. The correct version of this news story can be read at http://www.financial-market-news.com/brokerages-set-alnylam-pharmaceuticals-inc-alny-pt-at-59-85/1211611/.

Alnylam Pharmaceuticals (NASDAQ:ALNY) opened at 43.87 on Monday. The firm’s 50-day moving average is $40.00 and its 200 day moving average is $59.82. The stock’s market cap is $3.76 billion. Alnylam Pharmaceuticals has a 52 week low of $31.38 and a 52 week high of $109.10.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its earnings results on Wednesday, November 2nd. The biopharmaceutical company reported ($1.21) EPS for the quarter, missing the consensus estimate of ($1.14) by $0.07. The company had revenue of $13.70 million for the quarter, compared to analysts’ expectations of $9.14 million. Alnylam Pharmaceuticals had a negative return on equity of 33.97% and a negative net margin of 1,041.16%. Alnylam Pharmaceuticals’s revenue for the quarter was up 116.7% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.91) earnings per share. On average, equities research analysts expect that Alnylam Pharmaceuticals will post ($4.81) EPS for the current year.

In other Alnylam Pharmaceuticals news, Director David E. I. Pyott bought 27,900 shares of the company’s stock in a transaction that occurred on Thursday, October 13th. The stock was purchased at an average price of $37.00 per share, with a total value of $1,032,300.00. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Corporate insiders own 4.00% of the company’s stock.

Hedge funds have recently bought and sold shares of the company. Nisa Investment Advisors LLC acquired a new stake in Alnylam Pharmaceuticals during the second quarter worth about $128,000. Mn Services Vermogensbeheer B.V. increased its stake in Alnylam Pharmaceuticals by 4.6% in the third quarter. Mn Services Vermogensbeheer B.V. now owns 1,974 shares of the biopharmaceutical company’s stock worth $134,000 after buying an additional 87 shares during the period. Seven Eight Capital LLC increased its stake in Alnylam Pharmaceuticals by 200.0% in the first quarter. Seven Eight Capital LLC now owns 2,700 shares of the biopharmaceutical company’s stock worth $169,000 after buying an additional 1,800 shares during the period. Meeder Asset Management Inc. acquired a new stake in Alnylam Pharmaceuticals during the second quarter worth about $175,000. Finally, Bank of Montreal Can acquired a new stake in Alnylam Pharmaceuticals during the second quarter worth about $193,000. 89.81% of the stock is owned by hedge funds and other institutional investors.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in developing therapeutics based on ribonucleic acid (RNA) interference (RNAi). It is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate strategy for delivery of small interfering RNAs (siRNAs). Its pipeline of investigational RNAi therapeutics focuses in three Strategic Therapeutic Areas (STArs): Genetic Medicines; Cardio-Metabolic Disease, and Hepatic Infectious Disease.

5 Day Chart for NASDAQ:ALNY

Receive News & Ratings for Alnylam Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.